Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 5/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724986 | 0.90 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL5724044 | 0.89 | DAGLA (0.35) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL5723739 | 0.88 | ALDH1A1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL5724371 | 0.85 | HCRTR1 (0.36) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL5723833 | 0.85 | HCRTR1 (0.44) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL5724350 | 0.84 | HTR2C (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL5724184 | 0.83 | RIPK1 (0.39) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL5724359 | 0.83 | HCRTR1 (0.33) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL5724048 | 0.81 | — | — | |
| SCHEMBL5724097 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | TBXA2R 1822/4885RIPK1 2287/4885HCRTR1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.